872355-52-7

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 6-AMINO-2-METHYLNICOTINATE is used as an intermediate compound for the synthesis of pharmaceuticals, contributing to the development of various medications due to its unique chemical structure and properties.
Used in Agricultural Industry:
In agriculture, METHYL 6-AMINO-2-METHYLNICOTINATE is used as an intermediate in the production of agrochemicals, potentially enhancing crop protection and yield through its involvement in the synthesis of specific compounds.
Used in Chemical Synthesis:
METHYL 6-AMINO-2-METHYLNICOTINATE is utilized as a key intermediate in the synthesis of complex organic compounds, playing a crucial role in the creation of specialized chemicals for various applications across different industries.

InChI:InChI=1/C8H10N2O2/c1-5-6(8(11)12-2)3-4-7(9)10-5/h3-4H,1-2H3,(H2,9,10)

Upstream product

• 183428-90-2 2-amino-5-cyano-6-methylpyridine 
• 67-56-1 methanol 
• 680208-82-6 6-amino-2-methylpyridine-3-carboxylic acid? 
• 64-17-5 ethanol 
• 42753-71-9 5-bromo-6-methyl-pyridin-2-ylamine 

Downstream Products

• 872355-55-0 6-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 
• 872355-54-9 6-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester 
• 1429912-31-1 5-{[(1R,2S)-2-aminocyclohexyl]amino}-3-{[5-(dimethylcarbamoyl)-6-methylpyridin-2-yl]amino}pyridine-2-carboxamide 
• 1429914-11-3 tert-butyl {(1S,2R)-2-[(6-carbamoyl-5-{[5-(dimethylcarbamoyl)-6-methylpyridin-2-yl]amino}pyridin-3-yl)amino]cyclohexyl}carbamate 
• 1429914-08-8 ethyl 6-{[5-({(1R,2S)-2-[(tert-butoxycarbonyl)amino]cyclohexyl}amino)-2-cyanopyridin-3-yl]amino}-2-methylpyridine-3-carboxylate 
• 1429914-07-7 methyl 6-{[5-({(1R,2S)-2-[(tert-butoxycarbonyl)amino]cyclohexyl}amino)-2-cyanopyridin-3-yl]amino}-2-methylpyridine-3-carboxylate 

Relevant academic research and scientific papers

Structure-based drug design of novel and highly potent pyruvate dehydrogenase kinase inhibitors

Pyruvate dehydrogenase kinases (PDHKs) are fascinating drug targets for numerous diseases, including diabetes and cancers. In this report, we describe the result of our structure-based drug design from tricyclic lead compounds that led to the discovery of highly potent PDHK2 and PDHK4 dual inhibitors in enzymatic assay. The C3-position of the tricyclic core was explored, and the PDHK2 X-ray structure with a representative compound revealed a novel ATP lid conformation in which the phenyl ring of Phe326 mediated the interaction of the Arg258 sidechain and the compound. Compounds with amide linkers were designed to release the ATP lid by forming an intramolecular pi-pi interaction, and these compounds showed single-digit nM IC50 values in an enzymatic assay. We also explored the C4-position of the tricyclic core to reproduce the interaction observed with the C3-position substitution, and the pyrrolidine compound showed the same level of IC50 values. By optimizing an interaction with the Asn255 sidechain through a docking simulation, compounds with 2-carboxy pyrrole moiety also showed single-digit nM IC50 values without having a cation-pi interaction with the Arg258 sidechain.

NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE

Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.

2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

AZAINDOLE DERIVATIVES AS INHIBITORS OF P38 KINASE

The invention is directed to methods to inhibit p38 kinase, preferably p38-α using compounds which are azaindoles wherein the azaindoles are coupled through an azacyclic linker to another cyclic moiety.